Accolade (NASDAQ: ACCD) has announced that its stockholders have voted to approve the merger with Transcarent at the Accolade special meeting of stockholders. The final, certified voting results for the special meeting will be provided in a form 8-K filed with the U.S. Securities and Exchange Commission.
The transaction is expected to be completed in the second quarter of calendar year 2025, subject to customary closing conditions, including the receipt of certain state regulatory approvals. After the completion of the transaction, Accolade will become a privately held company, and shares of Accolade common stock will no longer be listed on any public market.
Advisors for the merger include Evercore as the exclusive financial advisor to Transcarent and Wilson Sonsini Goodrich & Rosati, Professional Corporation as the legal advisor to Transcarent. Meanwhile, Morgan Stanley & Co LLC serves as the exclusive financial advisor to Accolade, with Cooley LLP as the legal advisor to Accolade.
Accolade is a personalized healthcare company that provides millions of people and their families with exceptional healthcare experiences, offering virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. The company's consumer satisfaction ratings consistently exceed 90%.
No specific metrics or financial figures were provided in the press release. Today the company's shares have moved 0.1% to a price of $7.0. Check out the company's full 8-K submission here.
